Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Scientists launch world’s first antimicrobial medical gloves
Researchers expect the gloves to eventually sell in their billions, as healthcare providers battle to fight infection and combat antimicrobial resistance.
Gloves a "game changer" for the healthcare industry

The world’s first non-leaching antimicrobial gloves were launched yesterday (31 May) in London.

The gloves contain a new active microorganism-killing molecule designed to prevent the spread of bacteria. Because the technology is built into the material, the gloves don’t need surface applications of further solutions or testing.

In independent testing, the gloves achieved a 99.9 per cent kill within just five minutes of contact. University of Nottingham microbiologist Richard James, who helped with the project, said the gloves will be a “game-changer” for the healthcare industry.

“I am delighted that my lifetime’s research into bacteria and antibiotic resistance has directly informed the science behind a practical tool that will have a major impact on medical care in the future,” he said.

The gloves are the culmination of more than six years of research by Professor James, medical glove makers Hartalega Malaysia and development company Chemical Intelligence UK. They are expected to sell in their billions, as healthcare providers battle to fight infection and combat antimicrobial resistance.

“In the European Union alone, cross-contamination in hospitals results in 37,000 deaths a year at an additional cost of 7 billion euros,” said Mr Kuan Mun Leong, managing director of Hartalega Holdings. “By renovating a medical device that has not been remodelled in over 30 years, our innovation is set to make waves in the healthcare industry and save lives across the globe.”

Chemical Intelligence UK founder Rob Gross added: “After years of development, we are delighted to finally release this product to market and truly believe it will make a significant difference in the fight against healthcare-associated infections (HAIs). Like Hartalega, we have a passion for innovation and together we are the perfect partners to release this technology.”

Become a member or log in to add this story to your CPD history

Equine Disease Surveillance report released for Q4 2025

News Story 1
 The latest Equine Disease Surveillance report has been released, with details on equine disease from Q4 of 2025.

The report, produced by Equine Infectious Disease Surveillance, includes advice on rule changes for equine influenza vaccination.

Statistics and maps detail recent outbreaks of equine herpes virus, equine influenza, equine strangles and equine grass sickness. A series of laboratory reports provides data on virology, bacteriology, parasitology and toxicosis.

This issue also features a case study of orthoflavivus-associated neurological disease in a horse in the UK. 

Click here for more...
News Shorts
Applications open for BEVA Back in the Saddle

The British Equine Veterinary Association (BEVA) has opened applications for its 'Back in the Saddle' coaching programme.

The online scheme offers structured group coaching for members wanting to reflect on their career path and regain clarity. Members may be returning to work after leave, uncertain about next steps or reassessing direction.

Attendees will benefit from impartial guidance and practical tools to support their professional development. Members are encouraged to take a 'proactive, future-focused approach' to their careers.

The sessions, taking place on Wednesdays from 7.30pm-9pm, are open to BEVA members with more than five years' experience. The first session takes place on Wednesday, 3 June 2026.

Applications will close on Wednesday, 27 May 2026.